全球In Silico藥物發現市場：依技術平台、應用、最終用戶、實施模式和治療領域分類－2025年至2032年預測

預計到 2032 年，In Silico藥物發現市場將成長至 58.5 億美元，複合年成長率為 9.35%。

將電腦輔助藥物發現的戰略重要性定位為一項組織能力，該能力整合了資料科學、實驗檢驗和營運管治。

In Silico藥物發現正從一種輔助能力轉變為現代轉化研究的核心支柱，它融合了計算、數據和專業知識，加速藥物發現生命週期中的決策。本文將該領域定位為不僅僅是一套工具；它是一種綜合方法，可以縮短週期時間，提高假設質量，並在研發早期階段做出更有把握的「繼續/終止」決策。本文也展示如何將計算方法融入更廣泛的研發策略中，使之與實驗檢驗、監管要求和商業性需求保持一致不再是可選項，而是必要條件。

當今的格局呈現出多種相互作用的趨勢：生物數據的指數級成長、分子科學專用機器學習方法的日益成熟，以及運算能力透過雲端和本地環境的普及。這些因素共同作用，為團隊創造了一個能夠更有系統地探索化學空間、更精確地預測ADMET性質並從整合系統生物學的觀點篩選靶點的環境。因此，領導者必須超越孤立的概念驗證試點項目，著眼於建立可擴展的流程，使其具備可重複性、可解釋性，並促進計算科學家、藥物化學家和轉化生物學家之間的跨職能協作。

此外，從供應商合作到聯盟科研，協作經營模式的興起使得規模較小的組織也能獲得以往只有大型企業才能掌握的能力。這種能力獲取方式的重新平衡凸顯了編配能力的重要性——即協調資料來源、統一模型輸出以及整合外部服務供應商的能力，從而在最大限度地加快創新速度的同時保護智慧財產權。摘要，這種趨勢表明，In Silico藥物發現如今已成為一項組織能力，需要對策略、管治、人員和基礎設施進行投資才能持續創造價值。

計算方法、基礎設施規模和夥伴關係模式的進步正在匯聚，從根本上重塑藥物發現研究的搜尋策略和管治。

In Silico輔助藥物發現領域正經歷幾項變革性的轉變，這些轉變正在改變成功的定義和實現方式。首先，調查方法的融合正在產生更可靠的結果。基於物理的分子模擬正擴大與機器學習模型相結合，這些模型能夠從公共和專有資料集中學習，從而形成混合方法，既能捕捉機制層面的洞見，又能將預測擴展到大型化合物庫。這種整合需要新的跨學科人才和工作流程，以協調不同來源的不確定性和檢驗標準。

其次，基礎設施的成熟度提升了營運的擴充性。無論是本地叢集還是針對GPU工作負載最佳化的雲端實例，高效能運算資源的取得都使得運算密集型模擬和快速推理流程的日常運作成為可能。因此，各組織正從孤立的演算法實驗轉向將預測模型持續整合到藥物研發流程中，並輔以自動化資料管理和監控，以確保結果的可複現性。

第三，夥伴關係模式正在不斷演變。技術供應商、受託研究機構(CRO) 和生物製藥公司之間正在建立策略聯盟，共用專業知識、在安全管治下共享精選資料共用並加速標靶檢驗。這些合作得到了專業服務供應商生態系統的補充，這些提供者提供模組化功能，例如從頭分子設計引擎以及基於配體和結構的虛擬篩檢平台，使用戶能夠建立客製化的工具鏈。

最後，監管和倫理方面的考量正成為技術採納的核心要素。無論是內部管理機構或外部相關人員，對模型可解釋性、資料來源和可複現性的期望都在不斷提高。那些積極在其計算工作流程中建立審核和可解釋性的公司，更有能力應對監管審查，並與臨床和商業合作夥伴建立信任。這些變化通常並非漸進式的，而是正在重塑人才、技術和管治，使那些能夠運作複雜混合運算策略的組織更具優勢。

評估 2025 年美國實施的關稅對電腦輔助藥物發現操作中的採購、供應鏈韌性和採用決策的連鎖反應。

2025年的政策環境，尤其是美國的關稅，將對In Silico藥物發現生態系統產生多方面的影響，而不僅限於直接採購成本。關稅波動將影響關鍵硬體組件（例如GPU和專用加速器）的供應和價格，這些組件對於高通量分子模擬和深度學習模型訓練至關重要。進口關稅的上漲將延長採購週期，並改變資本預算決策，迫使各機構重新評估其運算基礎設施的更新週期，並優先考慮工作負載整合和雲端遷移，以降低前期投資風險。

除了硬體之外，關稅也會影響全球軟體和服務供應鏈。許多專業服務供應商和原始設備製造商 (OEM) 經營跨境製造和支援網路，而日益加劇的貿易摩擦使維護合約、備件物流和跨區域服務水平協議變得更加複雜。這些營運摩擦增加了本地部署系統的總擁有成本 (TCO)，促使企業轉向在貿易協定更為有利且擁有本地資料中心的地區部署雲端基礎服務。

從策略角度來看，關稅的不確定性將加速供應鏈多元化和區域化策略的推進。企業可能會尋求供應商冗餘，與服務供應商和合約研究機構建立本地夥伴關係，或考慮投資關鍵零件的國內生產能力。雖然這些措施可能增強韌性，但也可能增加短期整合和檢驗的負擔，因為團隊需要適應不同的工具鏈和支援模式。此外，由於供應商會尋求透過服務商品搭售和變更授權條款來抵銷利潤壓力，關稅可能會間接影響人才流動和與供應商的談判動態。

從專案角度來看，資費政策的影響凸顯了彈性部署架構的重要性。結合雲端爆發以應對高峰工作負載和本地平台處理敏感或延遲敏感任務的混合模式，既能應對成本波動，又能滿足資料主權要求。因此，決策者應將資費政策方案納入採購計畫和彈性評估，以確保計算服務的連續性，同時謹慎管理資本支出和營運支出。

可操作的細分資訊：映射平台架構、應用程式需求、部署偏好、最終用戶優先順序和領域限制，以針對性地建立能力。

理解細分市場對於使技術投資和組織優先事項與不同工作流程和使用者的特定需求保持一致至關重要。基於技術平台，應專注於運算化學和生物資訊學與高效能運算、機器學習/人工智慧和分子建模各自扮演的不同角色。每個平台細分市場都需要專門的資料工程流程、檢驗框架和人才組合，而整合這些平台則為混合方法提供了可能，這些方法可以將基於機制的模擬與資料驅動的預測相結合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• 透過整合人工智慧驅動的生成模型和結構生物資訊學，加速先導化合物的最佳化篩選
• 利用量子計算演算法模擬酵素-配體相互作用（用於複雜標靶檢驗）
• 引入多體學資料融合平台用於藥物反應表現型的預測建模
• 部署雲端原生高效能運算叢集以實現可擴展的分子動力學模擬
• 擴展我們的人工智慧藥物發現平台，將主動學習融入新型骨架發現。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按技術平台In Silico藥物發現市場

• 計算化學與生物資訊學
• 高效能運算
• 機器學習和人工智慧
• 分子建模

第9章 按應用分類In Silico藥物發現市場

• ADMET預測
  • 吸收預測
  • 分佈預測
  • 排泄預測
  • 代謝預測
  • 毒性預測
• 先導化合物的篩選與最佳化
  • 全新設計
  • 基於片段的最佳化
• 藥物動力學模型
• 目標識別與檢驗
• 虛擬篩檢
  • 基於配體的虛擬篩檢
  • 基於結構的虛擬篩檢

第10章In Silico藥物發現市場

• 學術研究機構
• CRO（受託研究機構）
• 製藥和生物技術公司

第11章 按部署模式In Silico藥物發現市場

• 雲端基礎的
• 本地部署

第12章 按治療領域In Silico藥物發現市場

• 循環系統
• 中樞神經系統
• 感染疾病
• 腫瘤學

第13章 區域性In Silico藥物發現市場

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章In Silico藥物發現市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 各國In Silico藥物發現市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • Dassault Systemes SE
  • Certara, Inc.
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • OpenEye Scientific Software, Inc.
  • Exscientia plc
  • Atomwise, Inc.
  • Insilico Medicine, Inc.
  • Cresset BioMolecular Discovery Ltd
  • Chemical Computing Group ULC

The In-Silico Drug Discovery Market is projected to grow by USD 5.85 billion at a CAGR of 9.35% by 2032.

Framing the strategic importance of computational drug discovery as an organizational competency that integrates data science, experimental validation, and operational governance

In-silico drug discovery is transitioning from a complementary capability to a central pillar of modern translational research, where computation, data, and domain expertise converge to accelerate decision-making across the discovery lifecycle. This introduction frames the discipline not merely as a set of tools but as an integrated approach that reduces cycle times, elevates hypothesis quality, and enables higher-confidence go/no-go decisions earlier in development. It also situates computational approaches within broader R&D strategies, where alignment with experimental validation, regulatory expectations, and commercial imperatives is increasingly mandatory rather than optional.

The contemporary landscape is characterized by multiple interacting forces: exponential growth in biological data, maturation of machine learning methods tailored to molecular science, and the commoditization of computational capacity through cloud and on-premise environments. These forces have produced an environment in which teams can explore chemical space more systematically, predict ADMET attributes with greater nuance, and triage targets through integrated systems biology perspectives. Consequently, leaders must think beyond isolated proof-of-concept pilots and toward scalable pipelines that embed reproducibility, explainability, and cross-functional handoffs between computational scientists, medicinal chemists, and translational biologists.

Furthermore, the rise of collaborative business models-ranging from vendor partnerships to consortium science-has enabled smaller organizations to access capabilities formerly exclusive to large pharmaceutical companies. This rebalancing of capability access places a premium on orchestration skills: the ability to coordinate data provenance, harmonize modeling outputs, and integrate external service providers in ways that preserve intellectual property while maximizing innovation velocity. In sum, the introduction underscores that in-silico drug discovery is now an organizational competency that requires strategy, governance, and investment in people and infrastructure to deliver sustained value.

How converging advances in computational methods, infrastructure scale, and partnership models are fundamentally reshaping discovery strategies and governance in drug research

The landscape of in-silico drug discovery is being reshaped by several transformative shifts that collectively change what success looks like and how it is achieved. First, methodological convergence is driving more robust outputs: physics-informed molecular simulation is increasingly combined with machine learning models that learn from both public and proprietary datasets, producing hybrid approaches that capture mechanistic insight while scaling predictions across large compound libraries. This convergence demands new interdisciplinary talent profiles and workflows that can reconcile different sources of uncertainty and validation criteria.

Second, infrastructure maturation is enabling operational scalability. Access to high-performance computing resources, whether on-premise clusters or cloud instances optimized for GPU workloads, permits the routine execution of computationally intensive simulations alongside rapid inference pipelines. As a result, organizations are shifting from isolated algorithmic experiments toward continuous integration of predictive models into discovery pipelines, with automated data curation and monitoring to ensure reproducibility.

Third, partnership models are evolving. Strategic alliances between technology vendors, contract research organizations, and biopharma companies are forming to pool domain knowledge, share curated datasets under secure governance, and accelerate target validation. These collaborations are complemented by an ecosystem of specialized service providers who offer modular capabilities-for example, de novo molecular design engines or ligand- and structure-based virtual screening platforms-enabling adopters to compose tailored toolchains.

Finally, regulatory and ethical considerations are becoming central to technology adoption. Expectations around model interpretability, data provenance, and reproducibility are increasing from both internal governance bodies and external stakeholders. Companies that proactively embed auditability and explainability into their computational workflows are better positioned to navigate regulatory scrutiny and build trust with clinical and commercial partners. Taken together, these shifts are not incremental; they reconfigure talent, technology, and governance in ways that favor organizations able to operationalize complex, hybrid computational strategies.

Evaluating how United States tariff measures enacted in 2025 cascade through procurement, supply chain resilience, and deployment decisions across computational drug discovery operations

The policy environment in 2025, including tariff actions originating from the United States, exerts multifaceted effects on in-silico drug discovery ecosystems that extend beyond immediate procurement costs. Tariff shifts influence the availability and pricing of critical hardware components such as GPUs and specialized accelerators, which are essential for high-throughput molecular simulation and deep learning model training. When import duties rise, procurement cycles elongate and capital budgeting decisions shift, prompting organizations to reevaluate refresh cadences for compute infrastructure and to prioritize workload consolidation or cloud migration to mitigate upfront capital exposure.

In addition to hardware considerations, tariffs affect the global software and service supply chain. Many specialized service providers and OEMs operate cross-border manufacturing and support networks; increased trade frictions complicate maintenance contracts, spare parts logistics, and multi-region service level agreements. These operational frictions can lead to higher total cost of ownership for on-premise systems and incentivize a rebalancing toward cloud-based deployments in jurisdictions with more favorable trade arrangements or local data center presence.

Strategically, tariff-driven uncertainty accelerates supply chain diversification and regionalization strategies. Organizations may pursue vendor redundancy, cultivate local partnerships with service providers and contract research organizations, or invest in domestic capacity for key components. Such moves can increase resilience but also raise near-term integration and validation burdens as teams adapt to heterogeneous toolchains and differing support models. Furthermore, tariffs can indirectly influence talent mobility and vendor negotiation dynamics, as suppliers seek to offset margin pressure through service bundling or altered licensing terms.

From a programmatic perspective, tariff impacts underscore the importance of flexible deployment architectures. Hybrid models that combine cloud bursting for peak workloads with on-premise platforms for sensitive or latency-dependent tasks enable teams to respond to both cost volatility and data sovereignty requirements. Decision-makers should therefore incorporate trade-policy scenarios into procurement planning and resilience assessments to ensure computational continuity while managing capital and operating expenditures prudently.

Actionable segmentation intelligence mapping platform architectures, application needs, deployment preferences, end-user priorities, and therapeutic area constraints for targeted capability building

Understanding segmentation is critical to aligning technical investments and organizational priorities with the specific demands of different workflows and users. Based on Technology Platform, attention should be paid to the distinct roles of Computational Chemistry and Bioinformatics versus High Performance Computing, Machine Learning and AI, and Molecular Modeling. Each platform segment requires tailored data engineering pipelines, validation frameworks, and talent mixes, and integrating these platforms creates opportunities for hybrid approaches that blend mechanistic simulation with data-driven prediction.

Based on Application, it is important to distinguish the varied requirements across ADMET Prediction, Lead Identification and Optimization, Pharmacokinetics Modeling, Target Identification and Validation, and Virtual Screening. ADMET Prediction itself decomposes into absorption prediction, distribution prediction, excretion prediction, metabolism prediction, and toxicity prediction, each demanding specialized datasets and domain-specific interpretability. Lead Identification and Optimization encompasses de novo design and fragment-based optimization approaches, which differ in their dependency on generative models versus expert-driven medicinal chemistry heuristics. Virtual Screening bifurcates into ligand-based virtual screening and structure-based virtual screening, with the former favoring cheminformatics and fingerprinting strategies and the latter relying on structural bioinformatics and docking accuracy.

Based on End User, differentiation among Academic and Research Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology Companies highlights divergent priorities: academic groups may prioritize methodological innovation and open science, contract research organizations emphasize reproducibility and throughput for client deliverables, and industry sponsors focus on regulatory robustness, IP protection, and integration with downstream clinical pipelines. Based on Deployment Model, the choice between Cloud Based and On Premise operations implicates governance, data residency, and cost structures, with hybrid approaches increasingly common to capture the benefits of both models.

Based on Therapeutic Area, the needs of cardiovascular, central nervous system, infectious diseases, and oncology programs vary in terms of target complexity, required assay validation, and tolerance for off-target liabilities. Oncology programs, for instance, often require sophisticated multi-omics integration and biomarker-driven validation, while infectious disease efforts may emphasize rapid screening and pathogen-specific constraint modeling. By mapping platform and application choices to end-user objectives and therapeutic constraints, organizations can more effectively prioritize investments and design fit-for-purpose workflows.

Regional capability patterns and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and partnership models

Regional context shapes how capabilities are adopted and scaled, influencing talent availability, regulatory expectations, and partnership ecosystems. In the Americas, there is a concentration of integrated biopharma organizations and a vibrant startup ecosystem that favors rapid prototyping, strong access to venture capital, and deep collaborations with clinical networks. These conditions support ambitious internal platforms and commercial partnerships, though they also require careful attention to IP strategy and compliance with evolving regulatory guidance.

In Europe, Middle East & Africa, the region presents a heterogeneous landscape where national research hubs and multinational centers of excellence coexist with growing public-private consortia. Regulatory harmonization efforts and strong emphasis on data protection influence preferred deployment models, often necessitating hybrid on-premise and cloud strategies that respect cross-border data transfer rules. Localized talent pools and strong academic links support method innovation, while strategic partnerships with contract research organizations help bridge scale and operational execution.

In the Asia-Pacific region, rapid expansion of computational capacity, strong government-backed initiatives, and a rising number of technology vendors are creating an environment conducive to large-scale adoption. This region often emphasizes cost-effective cloud solutions and regional data center investments, enabling high-throughput screening and model training at scale. However, differences in regulatory frameworks and language localization can introduce integration challenges, making regional partnerships and local compliance expertise critical for successful program deployment. Across all regions, organizations that align technical choices with local operational realities and partnership opportunities will achieve faster integration and greater resilience.

How differentiated technology capabilities, partnership models, and validation practices shape competitive positioning and long-term commercial relationships in computational discovery

Competitive dynamics in the in-silico drug discovery space are characterized less by single-vendor dominance and more by an ecosystem of specialized technology providers, platform integrators, and biopharma adopters forming modular value chains. Technology vendors differentiate through proprietary algorithms, curated training datasets, and the ability to integrate with laboratory automation and electronic laboratory notebook systems. Some firms emphasize physics-based simulation and molecular modeling, while others lead with generative chemistry and deep learning approaches, creating distinct value propositions for different stages of discovery.

Partnership archetypes include boutique technology providers collaborating with contract research organizations to offer end-to-end services, platform companies licensing core stacks to enterprise teams, and biopharma companies building internal centers of excellence that combine vendor solutions with in-house expertise. Strategic alliances between computational firms and large pharmaceutical organizations are common, and these relationships often center on co-development agreements, data-sharing frameworks, and joint validation studies that demonstrate translational relevance.

Additionally, service providers that can offer validated pipelines and regulatory-grade documentation gain preference among sponsors focused on clinical translation. The ability to demonstrate reproducibility, integrate with legacy IT systems, and meet stringent data governance requirements becomes a competitive differentiator. As a result, companies that invest in interoperability, transparent validation practices, and strong customer support tend to secure longer-term engagements and become preferred partners for enterprise-scale discovery initiatives.

Concrete strategic and operational priorities industry leaders must adopt to scale computational discovery from pilots to validated, production-grade drug discovery pipelines

Industry leaders should enact a coherent set of strategic and operational actions to convert computational promise into durable program outcomes. First, establish governance that ties computational objectives to therapeutic and portfolio goals, ensuring that model outputs feed directly into preclinical decision gates and that evaluation metrics are harmonized across teams. This alignment reduces friction when moving from pilot projects to production pipelines and clarifies investment priorities.

Second, invest in reproducibility and explainability. Embed version control for datasets and models, adopt standardized benchmarking protocols, and document workflows to support regulatory and audit requirements. These practices increase stakeholder confidence and reduce the risk of model drift or unintended biases affecting downstream experiments.

Third, architect flexible infrastructure. Adopt hybrid deployment patterns that allow for cloud elasticity during peak compute demands while preserving secure on-premise environments for sensitive data. Negotiate vendor contracts with clear service level agreements and redundancy provisions to mitigate supply chain disruptions and geopolitical risks.

Fourth, cultivate talent and cross-disciplinary collaboration. Build teams that combine computational scientists with medicinal chemists, pharmacologists, and regulatory experts to ensure that models are realistic, interpretable, and actionable. Provide continuous learning opportunities and create rotational programs that embed computational thinking across discovery functions.

Finally, pursue pragmatic partnerships and data strategies. Prioritize collaborations that provide curated, high-quality datasets with clear governance terms, and consider co-development agreements that share validation burdens. These steps accelerate time-to-impact while preserving strategic control over core IP and decision-critical datasets.

Transparent mixed-methods research protocol combining primary expert engagement, secondary literature synthesis, and multi-source data validation to ensure robust, actionable insights

The research approach underpinning this analysis combined qualitative expert engagement with structured secondary evidence synthesis and rigorous data validation protocols. Primary inputs were gathered through semi-structured interviews with domain experts spanning computational chemistry, machine learning, high-performance computing operations, and regulatory affairs, enabling direct insight into operational challenges, adoption barriers, and success factors observed in practice. These conversations were synthesized to surface common themes and divergent practices across organizational types.

Secondary evidence collection involved curated literature review of peer-reviewed methods papers, conference proceedings, technical white papers from technology providers, and publicly available regulatory guidance to triangulate claims and establish methodological baselines. Emphasis was placed on reproducibility and transparency, with methods and assumptions documented to permit independent review. Data validation employed cross-referencing across multiple independent sources, scenario testing to evaluate sensitivity to infrastructure and policy variables, and plausibility checks to ensure consistency with prevailing technology capabilities.

Limitations were acknowledged and addressed: primary interviews reflect experiential insights from a cross-section of organizations and are not exhaustive, and the pace of technological innovation means that specific tool capabilities evolve rapidly. To mitigate these constraints, the methodology prioritized durable patterns of behavior and structural dynamics over ephemeral product-level specifics. This mixed-methods design yields robust, actionable insights while making explicit the evidentiary basis for conclusions.

Consolidated conclusions emphasizing the necessity of governance, reproducibility, and deployment flexibility to realize sustained value from computational discovery programs

In conclusion, in-silico drug discovery is maturing into a strategic capability that requires deliberate organizational design, flexible infrastructure, and rigorous validation practices to deliver sustained translational value. The interplay of hybrid computational methods, evolving partnership models, and regional deployment realities creates both opportunities and operational complexities that leaders must navigate proactively. Those who align technical choices with therapeutic priorities, embed reproducibility and explainability into workflows, and pursue resilient procurement and deployment strategies will realize the greatest benefit.

Policy dynamics and supply chain pressures underscore the need for adaptable architectures and diversified vendor relationships, while segmentation-aware strategies ensure that investments map to the distinct needs of technology platforms, application types, end users, deployment models, and therapeutic areas. Ultimately, success depends on integrating computational insights into corporate decision-making processes and building cross-functional teams that can translate model outputs into decisive experimental actions. By treating in-silico discovery as a core competency rather than an auxiliary capability, organizations can accelerate the pathway from hypothesis to validated candidate while managing risk and preserving strategic optionality.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of AI-driven generative models with structural bioinformatics to accelerate hit-to-lead optimization
• 5.2. Adoption of quantum computing algorithms to simulate enzyme-ligand interactions for complex target validation
• 5.3. Implementation of multi-omics data fusion platforms for predictive modeling of drug response phenotypes
• 5.4. Deployment of cloud-native high-performance computing clusters for scalable molecular dynamics simulations
• 5.5. Expansion of AI-enabled de novo drug design platforms with active learning for novel scaffold discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Silico Drug Discovery Market, by Technology Platform

• 8.1. Computational Chemistry And Bioinformatics
• 8.2. High Performance Computing
• 8.3. Machine Learning And Ai
• 8.4. Molecular Modeling

9. In-Silico Drug Discovery Market, by Application

• 9.1. Admet Prediction
  • 9.1.1. Absorption Prediction
  • 9.1.2. Distribution Prediction
  • 9.1.3. Excretion Prediction
  • 9.1.4. Metabolism Prediction
  • 9.1.5. Toxicity Prediction
• 9.2. Lead Identification And Optimization
  • 9.2.1. De Novo Design
  • 9.2.2. Fragment Based Optimization
• 9.3. Pharmacokinetics Modeling
• 9.4. Target Identification And Validation
• 9.5. Virtual Screening
  • 9.5.1. Ligand Based Virtual Screening
  • 9.5.2. Structure Based Virtual Screening

10. In-Silico Drug Discovery Market, by End User

• 10.1. Academic And Research Institutes
• 10.2. Contract Research Organizations
• 10.3. Pharmaceutical And Biotechnology Companies

11. In-Silico Drug Discovery Market, by Deployment Model

• 11.1. Cloud Based
• 11.2. On Premise

12. In-Silico Drug Discovery Market, by Therapeutic Area

• 12.1. Cardiovascular
• 12.2. Central Nervous System
• 12.3. Infectious Diseases
• 12.4. Oncology

13. In-Silico Drug Discovery Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. In-Silico Drug Discovery Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. In-Silico Drug Discovery Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Dassault Systemes SE
  • 16.3.2. Certara, Inc.
  • 16.3.3. Schrodinger, Inc.
  • 16.3.4. Simulations Plus, Inc.
  • 16.3.5. OpenEye Scientific Software, Inc.
  • 16.3.6. Exscientia plc
  • 16.3.7. Atomwise, Inc.
  • 16.3.8. Insilico Medicine, Inc.
  • 16.3.9. Cresset BioMolecular Discovery Ltd
  • 16.3.10. Chemical Computing Group ULC

LIST OF FIGURES

• FIGURE 1. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. IN-SILICO DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 203. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 224. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 225. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 226. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 275. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 278. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 279. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 280. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 286. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 287. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 289. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)

TABLE